Business Context and Reporting Period
Company: Innovative Eyewear, Inc. (Ticker: LUCY)
Filing Type: Form 8-K (Current Report)
Reporting Date: July 9, 2026 (Event Date: July 8, 2026)
Context: The Company entered into an inducement letter agreement with a holder of existing warrants to facilitate a cash exercise of those warrants in exchange for the issuance of new warrants and a reduction in the exercise price.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $3.0 million (prior to deducting placement agent fees and offering expenses).
- Use of Proceeds: Working capital and general corporate purposes.
- Existing Warrants Exercised: 2,200,544 shares at a reduced exercise price of $1.35 per share (original price was $2.60).
- New Warrants Issued (Series J): 6,601,632 warrants at a purchase price of $0.125 per warrant; exercise price of $1.10 per share; 24-month term.
- Placement Agent Fees (H.C. Wainwright & Co., LLC):
- Cash Fee: 7.5% of gross proceeds.
- Management Fee: 1.0% of gross proceeds.
- Accountable Expenses: $50,000.
- Non-accountable Expenses: $25,000.
- Clearing Expenses: $15,950.
- PA Warrants: 165,041 warrants issued to the agent (exercise price $1.6875).
Material Changes and Agreements
The filing details a material definitive agreement involving a warrant exchange and inducement. Key changes include:
- Price Reduction: The exercise price for the existing warrants was reduced from $2.60 to $1.35 per share.
- Registration Rights: The Company agreed to file a resale registration statement for the new warrants within 15 calendar days and use commercially reasonable efforts to have it declared effective within 45 days (or 75 days if a full review is required).
- Lock-up Provisions:
- No issuance of Common Stock or equivalents for 30 calendar days post-closing (subject to exceptions).
- No Variable Rate Transactions for one year post-closing (subject to exceptions).
Outlook, Risks, and Contingencies
- Regulatory Risk: The transaction relies on the timely effectiveness of the Resale Registration Statement. Delays in SEC review could impact the liquidity of the new warrants.
- Dilution: The issuance of 6.6 million new Series J warrants and 165,041 PA warrants represents significant potential dilution to existing shareholders.
- Future Fees: The Company agreed to pay future fees (7.5% cash, 1.0% management, and 7.5% warrants) on the ordinary course exercise of warrants previously placed by H.C. Wainwright.
- Unregistered Sales: The new warrants were sold under Section 4(a)(2) and Rule 506 exemptions, meaning they cannot be resold in the U.S. absent registration or an exemption.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 8.5% cash fees and fixed expenses from the $3.0 million gross.
- Review the attached Inducement Letter Agreement (Exhibit 10.1) for specific exceptions to the lock-up provisions.
- Monitor the status of the Resale Registration Statement to ensure it becomes effective within the 45-day target window.
- Assess the impact of the 6.6 million new warrants on the Company's fully diluted share count.
- Confirm the Company's current cash position to ensure the $3.0 million infusion is sufficient for stated working capital needs.